Two New Post-Hoc Analyses of TRA 2°P TIMI 50 Study Showed ZONTIVITY® (vorapaxar) Added to Aspirin and/or Clopidogrel Reduced Acute Limb Ischemia and Peripheral Revascularizations, Respectively, in Certain Patients with Peripheral Arterial Disease
Dateline City:
KENILWORTH, N.J.
These and other post-hoc subgroup analyses from TRA-2°P are being presented at the 2015 American College of Cardiology Scientific Sessions
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK),
known as MSD outside the United States and Canada, today announced
results from two post-hoc analyses of the TRA 2°P TIMI 50 (Thrombin
Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic
Events) trial of ZONTIVITY® (vorapaxar), one of the largest secondary
prevention studies of an antiplatelet medicine.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
More News: Aspirin | Cardiology | Clopidogrel | Drugs & Pharmacology | Heart | Merck | Plavix | Study